FOLH1 and neoplasm: 225Ac-labelled trastuzumab as well as [225Ac]Ac-macropa-RPS-070 (targeting PSMA) showed high in vivo stability and good tumour targeting properties with low activity found in other organs, making it an interesting alternative in complexing actinium-225.